vs
Emergent BioSolutions Inc.（EBS）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
Emergent BioSolutions Inc.的季度营收约是RESOURCES CONNECTION, INC.的1.3倍（$148.7M vs $117.7M），RESOURCES CONNECTION, INC.净利率更高（-10.8% vs -36.7%，领先26.0%），RESOURCES CONNECTION, INC.同比增速更快（-19.2% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $15.6M），过去两年RESOURCES CONNECTION, INC.的营收复合增速更高（-11.8% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
EBS vs RGP — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $117.7M |
| 净利润 | $-54.6M | $-12.7M |
| 毛利率 | 42.9% | 37.1% |
| 营业利润率 | -18.8% | -10.3% |
| 净利率 | -36.7% | -10.8% |
| 营收同比 | -23.6% | -19.2% |
| 净利润同比 | -74.4% | 81.6% |
| 每股收益（稀释后） | $-0.95 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $148.7M | $117.7M | ||
| Q3 25 | $231.1M | $120.2M | ||
| Q2 25 | $140.9M | $139.3M | ||
| Q1 25 | $222.2M | $129.4M | ||
| Q4 24 | $194.7M | $145.6M | ||
| Q3 24 | $293.8M | $136.9M | ||
| Q2 24 | $254.7M | $148.2M | ||
| Q1 24 | $300.4M | $151.3M |
| Q4 25 | $-54.6M | $-12.7M | ||
| Q3 25 | $51.2M | $-2.4M | ||
| Q2 25 | $-12.0M | $-73.3M | ||
| Q1 25 | $68.0M | $-44.1M | ||
| Q4 24 | $-31.3M | $-68.7M | ||
| Q3 24 | $114.8M | $-5.7M | ||
| Q2 24 | $-283.1M | $10.5M | ||
| Q1 24 | $9.0M | $2.5M |
| Q4 25 | 42.9% | 37.1% | ||
| Q3 25 | 62.8% | 39.5% | ||
| Q2 25 | 52.5% | 40.2% | ||
| Q1 25 | 60.2% | 35.1% | ||
| Q4 24 | 39.4% | 38.5% | ||
| Q3 24 | 54.9% | 36.5% | ||
| Q2 24 | -18.8% | 40.2% | ||
| Q1 24 | 49.2% | 37.0% |
| Q4 25 | -18.8% | -10.3% | ||
| Q3 25 | 33.1% | -1.7% | ||
| Q2 25 | 1.1% | -47.0% | ||
| Q1 25 | 22.5% | -38.4% | ||
| Q4 24 | -4.9% | -52.7% | ||
| Q3 24 | 22.0% | -3.5% | ||
| Q2 24 | -79.9% | 7.6% | ||
| Q1 24 | 13.2% | 2.8% |
| Q4 25 | -36.7% | -10.8% | ||
| Q3 25 | 22.2% | -2.0% | ||
| Q2 25 | -8.5% | -52.6% | ||
| Q1 25 | 30.6% | -34.0% | ||
| Q4 24 | -16.1% | -47.2% | ||
| Q3 24 | 39.1% | -4.2% | ||
| Q2 24 | -111.2% | 7.1% | ||
| Q1 24 | 3.0% | 1.7% |
| Q4 25 | $-0.95 | $-0.38 | ||
| Q3 25 | $0.91 | $-0.07 | ||
| Q2 25 | $-0.22 | $-2.21 | ||
| Q1 25 | $1.19 | $-1.34 | ||
| Q4 24 | $-0.45 | $-2.08 | ||
| Q3 24 | $2.06 | $-0.17 | ||
| Q2 24 | $-5.38 | $0.31 | ||
| Q1 24 | $0.17 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $89.8M |
| 总债务越低越好 | $589.7M | — |
| 股东权益账面价值 | $522.6M | $194.6M |
| 总资产 | $1.3B | $289.3M |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
| Q4 25 | $205.4M | $89.8M | ||
| Q3 25 | $245.5M | $77.5M | ||
| Q2 25 | $267.3M | $86.1M | ||
| Q1 25 | $149.1M | $72.5M | ||
| Q4 24 | $99.5M | $78.2M | ||
| Q3 24 | $149.9M | $89.6M | ||
| Q2 24 | $69.7M | $108.9M | ||
| Q1 24 | $78.5M | $113.8M |
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
| Q4 25 | $522.6M | $194.6M | ||
| Q3 25 | $582.5M | $206.4M | ||
| Q2 25 | $536.2M | $207.1M | ||
| Q1 25 | $552.7M | $277.8M | ||
| Q4 24 | $482.8M | $325.7M | ||
| Q3 24 | $508.4M | $407.2M | ||
| Q2 24 | $386.3M | $418.8M | ||
| Q1 24 | $663.9M | $414.9M |
| Q4 25 | $1.3B | $289.3M | ||
| Q3 25 | $1.5B | $287.2M | ||
| Q2 25 | $1.4B | $304.7M | ||
| Q1 25 | $1.4B | $375.6M | ||
| Q4 24 | $1.4B | $424.9M | ||
| Q3 24 | $1.5B | $512.9M | ||
| Q2 24 | $1.5B | $510.9M | ||
| Q1 24 | $1.8B | $523.2M |
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $15.6M |
| 自由现金流率自由现金流/营收 | 49.6% | 13.2% |
| 资本支出强度资本支出/营收 | 2.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $156.8M | $24.3M |
8季度趋势，按日历期对齐
| Q4 25 | $77.7M | $15.9M | ||
| Q3 25 | $-2.3M | $-7.8M | ||
| Q2 25 | $106.4M | $16.8M | ||
| Q1 25 | $-11.2M | $659.0K | ||
| Q4 24 | $-79.9M | $1.8M | ||
| Q3 24 | $153.7M | $-309.0K | ||
| Q2 24 | $47.5M | $3.2M | ||
| Q1 24 | $-62.6M | $20.5M |
| Q4 25 | $73.8M | $15.6M | ||
| Q3 25 | $-5.7M | $-8.0M | ||
| Q2 25 | $103.5M | $16.5M | ||
| Q1 25 | $-14.8M | $238.0K | ||
| Q4 24 | $-81.6M | $61.0K | ||
| Q3 24 | $147.9M | $-575.0K | ||
| Q2 24 | $42.9M | $3.0M | ||
| Q1 24 | $-73.4M | $20.4M |
| Q4 25 | 49.6% | 13.2% | ||
| Q3 25 | -2.5% | -6.6% | ||
| Q2 25 | 73.5% | 11.8% | ||
| Q1 25 | -6.7% | 0.2% | ||
| Q4 24 | -41.9% | 0.0% | ||
| Q3 24 | 50.3% | -0.4% | ||
| Q2 24 | 16.8% | 2.1% | ||
| Q1 24 | -24.4% | 13.5% |
| Q4 25 | 2.6% | 0.3% | ||
| Q3 25 | 1.5% | 0.1% | ||
| Q2 25 | 2.1% | 0.2% | ||
| Q1 25 | 1.6% | 0.3% | ||
| Q4 24 | 0.9% | 1.2% | ||
| Q3 24 | 2.0% | 0.2% | ||
| Q2 24 | 1.8% | 0.1% | ||
| Q1 24 | 3.6% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | -6.96× | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
